CTOs on the Move

Aruna Biomedical

www.arunabio.com

 
ArunA Bio is harnessing the natural abilities of neural exosomes to cross the blood brain barrier and enhance the body`s anti-inflammatory, self-repair and protective mechanisms to treat a range of neurodegenerative disorders.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Aruna Biomedical raised $13M on 07/24/2019
Aruna Biomedical raised $10.8M on 04/14/2021

Similar Companies

Pendulum Therapeutics

Pendulum is committed to developing novel interventions that target the human microbiome to improve the lives of patients suffering from a variety of diseases. Our targeted formulations of natural bacterial strains help to rebalance the microbiome which restores and improve one`s health.

iPierian

iPierian is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Mid Atlantic Technology and Enviromental Research In

Mid Atlantic Technology and Enviromental Research In is a Castle Hayne, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DYNAMIS THERAPEUTICS

DYNAMIS THERAPEUTICS is a Jenkintown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genelux

Genelux is a late clinical-stage biopharmaceutical company focused on developing a pipeline of next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. The Company`s most advanced product candidate, Olvi-Vec (olvimulogene nanivacirepvec), is a proprietary, modified strain of the vaccinia virus. Olvi-Vec currently is being evaluated in OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination with platinum-doublet + bevacizumab compared to platinum-doublet + bevacizumab in patients with platinum-resistant/refractory ovarian cancer. The core of Genelux` discovery and development efforts revolves around the company`s proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec.